Ménière's disease (MD) is a complex inner ear disorder defined by endolymphatic hydrops and a triad of episodic vertigo, fluctuating hearing loss, and tinnitus. Despite AAO-HNS diagnostic guidelines, disease heterogeneity and lack of treatment consensus persist....
✦ The floor
Discussion
Signed responses from readers of the wire.
Treatment evidence for Ménière's disease remains highly variable in quality; audiologists and ENT colleagues should interpret guideline recommendations cautiously until higher-quality RCTs close the evidence gaps identified.
Scoping the three-decade evidence landscape for Ménière's disease directly exposes gaps that should guide future trial design and temper over-confident clinical guidelines.
- 01Scoping review spans 30 years of Ménière's disease treatment research.
- 02Highlights trends in treatment approaches alongside systematic evaluation of evidence quality.
- 03Episodic vertigo, fluctuating hearing loss, and tinnitus define the condition under review.
- 04Identifies where evidence is weak and where stronger trial designs are needed.
- 05Findings can inform prioritisation of future clinical research funding.
Evidence quality for Ménière's disease treatments has been variable across three decades of published research.
studysupported- PMID
- 42053150
- DOI
- 10.1002/lary.70596.
- Journal
- The Laryngoscope
- Publication type
- review
- Evidence level
- 1a
- Population
- Published studies covering patients with Ménière's disease over a 30-year period
- Intervention
- All reported treatments for Ménière's disease
Primary outcomes
Treatment trends over three decades; Evidence quality of Ménière's disease treatment studies